Oestradiol is a well-characterized sex hormone that stimulates breast cancer and other oestrogen-related diseases. 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyses the last step in the synthesis of oestradiol and androstenediol in breast tumour tissue. The enzyme's high expression and activity after simultaneous blockade of oestrogen receptors and inhibition of aromatase in the tumour shows the necessity for its inhibition as a requirement for breast cancer therapy. In the present paper, we report structures of the binary and ternary complexes of 17β-HSD1 with a new inhibitor E 2 B {3-[3 ,17 β-dihydroxyestra-1 ,3 ,5 (10 )-trien-16 β-methyl]benzamide}, and the enzyme inhibition by the later. The IC 50 value for E 2 B was determined to be 42 nM in T47D cells. Multiple interactions between E 2 B and the enzyme include hydrogen bonds and hydrophobic interactions, as well as π-π interactions. A kinetic study demonstrated that E 2 B inhibits the enzyme's reduction forming oestradiol from oestrone, with a K i of 0.9 + − 0.15 nM. Such strong inhibition is in agreement with its extensive interaction with the enzyme, suggesting its potential as a lead compound for breast cancer therapy. In fact, this possibility is enhanced by its capacity for cell penetration similar to natural steroids. Such inhibitors that block oestrogen synthesis to suppress the sulfatase pathway producing oestradiol can be used in adjuvant therapies with oestrogen receptor blockade, opening a new orientation of breast cancer treatment.
INTRODUCTION
The potent oestrogen, E 2 (oestradiol), has been a well-known factor responsible for the stimulation of breast cancer and is also implicated in other oestrogen-related diseases. It is also involved in the genesis and development of diseases in certain genetic and phenotypic cases. The American Cancer Society estimated that within 2008, 182 460 cases of breast cancer would be reported, leading to 40 480 deaths. In 2008, an estimated 22 400 women were diagnosed with breast cancer in Canada alone, resulting in 5300 deaths, of which most were E 2 -dependent. Breast cancer continues to lead in incidence among North American women, with more than twice as many new cases as lung cancer.
The biological activity of steroid hormones is regulated at the pre-receptor level by several enzymes, including 17β-HSDs (17β-hydroxysteroid dehydrogenases). 17β-HSD1 is the first member known in this family to catalyse the last step in the synthesis of E 2 [1] [2] [3] [4] . To date, it also possesses the highest activity for oestrogen synthesis in the 17β-HSD family towards the reduction reaction [5] . The first detailed enzyme activity measurements applied to the homogeneous and fully active enzyme preparation appeared in 1992 [6] , which laid down the basis of crystallization and the enzyme homodimeric structure solution.
Most 17β-HSDs belong to the SDR (short-chain dehydrogenase-reductase) family, with the exception of type 5, which is an aldo-keto reductase. 17β-HSDs of the SDR family share several common amino acid sequence motifs [7] [8] [9] [10] [11] . Even though many 17β-HSD members are ubiquitously present in different tissues, they demonstrate distinct preferences for either the activation or inactivation of different steroid hormones [12] . For the enzymes using triphosphate cofactors, they are usually reductive in cells, where [NADPH]>[NADP] [13] . On the other hand, those using diphosphate cofactors are generally oxidative in cells as [NAD] >[NADH] ( [13] and references therein). Besides the general gonadal supply of sex steroids, there is the other and important intracrinological provision by peripheral steroid synthesis (e.g. adrenal, skin or brain) and steroid activationinactivation (epithelial cells of breast, uterus, prostate or kidney). In addition adrenal steroid precursor is delivered in the form of DHEA (dihydroepiandrosterone) sulfate and E 1 S (oestrone sulfate) to the peripheral tissue where they are converted into oestrogens and androgens.
Two principal pathways are involved in the last steps of E 2 synthesis in breast cancer: the 'aromatase pathway' which transforms androgens into oestrogens and the 'sulfatase pathway' which converts E 1 S into E 1 (oestrone) and then, by the action of 17β-HSD1, into E 2 . Previous studies have reported that, in human breast tumours, the sulfatase pathway predominates over the aromatase pathway [14, 15] . Despite low levels of circulating oestrogens, the concentration of E 2 in cancer tissue is several times higher than found in plasma and is also higher in postmenopausal than in pre-menopausal patients, suggesting a specific tumoral biosynthesis and hormone accumulation [16, 17] . In addition to the synthesis of E 2 , which stimulates breast cancer [18] [19] [20] , higher mRNA expression levels for 17β-HSD1, but not for aromatase or sulfatase, is found in post-menopausal breast cancers [18] . The latter indicates the important role played by 17β-HSD1. Oestrogens are reported to be essential for the growth and differentiation of the mammary gland, and tumour formation may originate from excessive hormonal stimulation of breast epithelium [18] . Moreover 17β-HSD1 mRNA is a prognostic marker for breast cancer progression regardless of the ER (oestrogen receptor) status [19] . A high level of 17β-HSD1 correlates with an increased risk of developing a late relapse of breast cancer in ER-positive breast cancer patients [21, 22] . Purohit et al. [23] have shown that, in breast tumour tissues, the reductive direction of oestrogen metabolism prevails and there is the possibility that tumour-derived factors might modulate the activity of 17β-HSD1. Growth factors [e.g. IGF (insulinlike growth factor)-I and IGF-II] and cytokines [IL (interleukin)-6 and TNFα (tumour necrosis factor α)] have been shown to stimulate the activity of 17β-HSD1 in breast tumour tissue [23] . Sasano et al. [24, 25] have analysed clinical data and shown that no correlation was detected for intratumoral aromatase and 17β-HSD1, demonstrating that intratumoral E 2 was produced by a pathway other than aromatase in certain breast cancer patients [25] . For patients in whom overexpression of intratumoral 17β-HSD1, but not aromatase, is detected, inhibition of 17β-HSD1 could be of much more importance than inhibition of aromatase.
In gonadal and peripheral tissues, 17β-HSD1 is the most important oestrogen-activating enzyme [3, 26] . 17β-HSD1 can convert less active oestrogens such as E 1 into more potent forms, first from E 1 into E 2 and secondly from DHEA into androstenediol [3] , whereas 17β-HSD7 possesses a significantly lower activity for conversion of E 1 into E 2 . Both 17β-HSD1 and 17β-HSD2 are known to be expressed in normal breast tissue, but higher expression of 17β-HSD1 mRNA has been demonstrated in almost 50 % of breast cancer tissues [20] . This suggests that the accumulation of E 2 in breast cancer cells as 17β-HSD2 is known to deactivate E 2 by its conversion into E1, which is less potent and has lower oestrogenic activity. In addition, 17β-HSD1 has been reported to be responsible for intracellular accumulation of E 2 in malignant breast epithelial cells. This suggests that the presence of 17β-HSD1 in cancerous tissue leads to increased proliferation of oestrogen-dependent cancer cells and breast cancer development [3, 20, 23] .
Knowledge of the function of 17β-HSD1 was quite limited before its three-dimensional structure was determined. The first diffraction-quality crystals were obtained in the early 1990s [27] , and the enzyme structure was determined to a resolution of 2.2 Å (1 Å = 0.1 nm), becoming the first three-dimensional structure of any human steroid-converting enzyme [9, 28] . A dozen different complex structures have been solved to date [9, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] . Although the enzyme can bind both NADH and NADPH, NADPH is the cognate cofactor rich in cells and drives the substrate reduction in vivo [13] , as NADPH is the major form of the triphosphate cofactor.
The enzyme's structure-activity relationship has been well documented, but to date progress in the design of an inhibitor that is effective for clinical trials has not been achieved [38] [39] [40] [41] [42] . However, inhibitors of 17β-HSDs constitute a growing interest in biomedical research, and new compounds have been developed in recent years [38] [39] [40] [41] [42] . One of these inhibitors, the E 2 -adenosine hybrid compound EM-1745, revealed key interactions with two different enzyme-binding sites, namely the substrate-and the cofactor-binding sites [36] . For the phenylmethyl derivatives (such as E 2 B {3-[3 ,17 β-dihydroxyoestra-1 ,3 ,5 (10 )-trien-16 β-methyl]benzamide}), our results suggest that the presence of a short flexible 16β-methylene group allows improved positioning of the phenyl ring to facilitate interaction with loop residues in the presence of the cofactor along with high affinity and drug-like quality.
In the present study, we have solved crystal structures of 17β-HSD1 in binary and ternary complexes with the new inhibitor E 2 B, and the cofactor NADP + along with a detailed kinetic study. The crystal structures of both binary and ternary structures of any inhibitor complex with 17β-HSD1 reported in the present study demonstrated the high affinity of the inhibitor for the enzyme and also provides an atomic-level insight into the structure-based efficiency of the inhibitor, detailing its interaction and scope for further development.
MATERIALS AND METHODS

Protein purification
Oestrogenic 17β-HSD1 was purified from human placenta by a procedure consisting of three FPLC steps using Q-Sepharose, Blue-Sepharose and phenyl-Sepharose affinity columns as described in the protocol used by Lin and colleagues [6] . β-OG (β-octylglucoside) was added to the protein thus obtained, which was then concentrated to 16 mg/ml. The protein concentration was determined by spectrophotometry and its activity was measured by the oxidation of E 2 to E 1 .
Inhibitor E 2 B
The inhibitor E 2 B ( Figure 1A ) was easily synthesized from E 1 by three chemical reactions consisting of an aldol condensation with 3-amidobenzaldehyde, a stereoselective carbonyl reduction and a stereoselective double-bond hydrogenation, which was published previously for closely related compounds [40] . The inhibitory curves of E 2 B and E 1 show the transformation of [4- 14 C]E 1 (60 nM) into [4- 14 C]E 2 in T47D intact cells. This experiment was performed as described previously [40] . The IC 50 value (the inhibition concentration at which 50 % of the enzyme activity is inhibited) was calculated using an unweighted iterative leastsquares method for four-parameter logistic curve fitting (DE50 program; CHUL Research Center).
Inhibition study
A radioactive assay was used to determine the enzyme steadystate kinetics first to calculate the K m for E 1 reduction into E 2 by 17β-HSD1 and then the same kinetics in the presence of E 2 B at different concentrations for the K i determination, similar to Qiu et al. [43] . The reactions were carried out in the presence of an excess of NADPH (50 μM) at pH 7.4 at 37 + − 0.5
• C. The K m for E 1 reduction into E 2 in the absence of E 2 B and different apparent K m values in the presence of 0.01-5 nM E 2 B were determined. At concentrations above 2 nM of E 2 B, total inhibition of the enzyme activity was obtained (results not shown).
The stock enzyme at 1.06 mg/ml was diluted with a buffer containing 50 mM Tris/HCl (pH 7.5), 20 % glycerol, 1 mM EDTA and 0.2 mM DTT (dithiothreitol) to a final concentration of 1.06 × 10 −5 mg/ml for kinetic studies. Reactions were initiated by the addition of the diluted enzyme sample to the reaction mixture resulting in the conversion of E 1 into E 2 . Aliquots were taken and the reaction was stopped at different time intervals (0, 3, 8 and 20 min) followed by steroid extractions with 2.5 × volume of diethyl ether. The steroids were separated by TLC migration in 80% toluene and 20 % acetone, and analysed by phosphoimaging. Initial velocities were measured with less than 5 % substrate consumption. The experiments were repeated with different concentrations of E 1 ranging from 0.01 to 0.2 μM. To obtain an optimal signal, larger reaction mixture volumes were used for low substrate concentrations (i.e. 1 ml reaction mixtures for 0.01, 0.02 and 0.05 μM E 1 , and 0.5 ml reaction mixture for The values were calculated using the following equations:
where v is the initial velocity in the presence of different substrate concentrations, V max is the maximum velocity, and [S] and [I] are the substrate and inhibitor concentrations ( Figure 1C , plots 1 and 2) [44] . The respective apparent K m values in the presence of different inhibitor concentrations were then plotted against these concentrations as shown by the kinetic plots in plot 3 of Figure 1 (C), the slope of which defines K m /K i [40] , based on the linear regression of
Crystallization
Crystals of the apoenzyme using protein at 16 mg/ml were obtained using the vapour-diffusion method in a hanging-drop set-up with 1 ml of well solution consisting of 27 % PEG [poly(ethylene glycol)] 4K, 100 mM Hepes buffer (pH 7.5), 0.16 mM MgCl 2 and 20 % glycerol at 27
• C [26] . The ratio of the protein to well solution, which yielded the best quality crystals, was 1.2:1.8 by vol. Apoenzyme crystals appeared in 2 days and were then soaked by slowly adding inhibitor E 2 B to the drop repeatedly over 2 weeks with a total addition of 3 mM E 2 B [45] . The ternary complex was obtained from the binary complex by soaking with NADP + to a final concentration of 6 mM for an additional week before data were collected.
Data collection
Data collection was carried out using R-axis-IIc image plate detector on a Rigaku RU-200 rotating anode with the normal focus 0.5 mm × 10 mm filament with copper anode at our home facility, using mineral oil as a cryoprotectant at 100 K. The crystals diffracted to a resolution of ∼ 2.2 and ∼ 2.0 Å for the binary and ternary complexes respectively.
Structure determination
Data were reduced using the XDS package, and the structures were solved using difference Fourier method using the atomic co-ordinates for 17β-HSD1 binary complex with E 2 (PDB code 1IOL) and the ternary complex with E 2 and NADP + (PDB code 1FDT). The structural parameters for the inhibitor E 2 B were generated using the sketcher module present in CCP4 version 5.0.2 software and was refined using Refmac5 also in CCP4. The complex structures were subjected to multiple rounds of refinement using Refmac, alternating with manual inspection in the program Coot [46] based on the σ A -weighted F o −F c electrondensity maps. The R free factor reflections were identical with those used previously to monitor the refinement of 17β-HSD1 complexes with steroids.
RESULTS
17β-HSD1 inhibition by E 2 B
The inhibitor E 2 B consists of a steroid core (E 2 ) and a carbonyl phenyl ring at position 16 of the steroid backbone linked by a methylene group ( Figure 1A) . The IC 50 value of E 2 B was determined with intact cells expressing 17β-HSD1 as mentioned by Laplante et al. [40] . Although E 2 B inhibited the transformation of E 1 into E 2 in transfected HEK (human embryonic kidney)-293 cells, T47D and MCF-7 breast cancer cells, its best potency was obtained with intact T47D cells. This is in correlation with the study which details the significantly higher expression of 17β-HSD1 in T47D cells than in MCF-7 cells, and also, in transfected HEK-293 cells, the presence of the cofactor can drive the reaction to either direction [21] . In the latter cells, the IC 50 value was determined to be 42 nM ( Figure 1B) . To assess the unwanted oestrogenic activity as E 2 B is a steroid derivative, a 10-day treatment with E 2 B at a concentration of 0.5 μM, which is more than 10-fold higher than its IC 50 with T47D cells, induced some proliferation (38 %) of T47D oestrogen-receptor-positive breast cancer cells. Interestingly, when E 2 B (0.5 μM) was given with E 1 (0.1 nM) in a 10-day treatment, it blocked 62 % of the T47D cell proliferation induced by E 1 after its reduction to E 2 by 17β-HSD1 [40] . To verify whether E 2 B was acting as an anti-oestrogen, an inhibition study in the presence of E 2 along with anti-oestrogen EM-139 was carried out. E 2 B did not reverse the proliferative effect on oestrogen-receptor-positive cells by E 2 (0.1 nM) as does the pure anti-oestrogen EM-139, thereby confirming that E 2 B does not act as an anti-oestrogenic compound, but as an inhibitor of 17β-HSD1 [40] . As shown in Figure 1 (C), plots 1 and 2, the Lineweaver-Burk plots for E 1 reduction to E 2 in the absence and the presence of different E 2 B concentrations intersect at the same point on the 1/v axis. For the reciprocal plots corresponding to different inhibitor concentrations, the curves in the presence of increasing inhibitor concentration result in a higher slope, pivoting around the intersection point on the control curve. This demonstrates a typical reversible and competitive inhibition by E 2 B against E 1 , in agreement with equation [1] . E 2 B, as expected from the formation of the ternary complex, showed non-competitiveness with NADPH (results not shown). The results also agree with the inhibitor-binding position in the substrate site shown by the crystallographic structure. A K i value of 0.9 + − 0.15 nM was calculated from the plot ( Figure 1C, plot 3) by the intersection of the above line on the left of the [I] axis, which demonstrates a higher affinity than any other available inhibitor for 17β-HSD1 in the literature. E 2 B shows a strong enzyme inhibition and a significantly higher apparent affinity for the enzyme than does E 1 . The K m for E 1 reduction by 17β-HSD1 was measured to be approx. 0.03 μM, a result similar to that found by Jin and Lin [5] . Such an inhibition by E 2 B is in agreement with its extensive interaction with the 17β-HSD1-binding pocket as observed in the enzyme-E 2 B complex structures.
Structure determination of the enzyme-inhibitor complexes
Both the binary and ternary complexes crystallized in space group C2 1 with one molecule in the asymmetric unit. The R-factor values for 17β-HSD1-E 2 B and 17β-HSD1-E 2 B-NADP + are shown in and Gly 198 in the binary complex at 1.8 σ . In the ternary complex at 1.8 σ level, all residues showed clear electron density except for Met 193 . These residues which did not show clear electron density in other structures constitute the active-site loop region from residues 189 to 200 of the enzyme. Electron density was clearly seen in the 2F o −F c map for the region constituting the loop at 1σ level (Figures 2A and 2B ). After the initial refinement, the F o −F c electron-density map is unambiguous for inhibitor E 2 B at the substrate-binding site in both the binary and ternary complexes. In the ternary complex, the electron density of the adenosine ring, the nicotinamide ring and the phosphate groups of NADP + was obvious, whereas that for ribose was unclear even after the final refinement. In the binary complex, the density of the benzylamide group of the inhibitor did suggest the presence of two conformations ( Figure 2C ). + . However, at higher σ -levels (>1.8), a discontinuity in the electron density becomes evident in both cases and more pronounced for the binary complex (not shown). (C) Black represents the conformation of E 2 B in the binary complex, and grey shows the conformation in the ternary complex along with the 2F o −F c electron-density map for the E 2 B in the binary complex map. It is observed that the electron density for the alternative conformation in the binary complex is similar to the conformation of E 2 B present in the ternary complex.
Apart from the hydrogen-bonding and hydrophobic interactions, a π-π interaction is present between Tyr 155 and the benzylamide ring of E 2 B. The smallest distance between Cε 1 of Tyr 155 and C-23 of E 2 B is 3.45 Å ( Figure 4A ) and the distance between the centres of the planes of the two phenyl rings is approx. 4.3 Å. The latter distance was determined by first calculating the centroids of the two phenyl rings of E 2 B and Tyr 155 followed by the distance between these two points. These values suggest that Tyr 155 and the phenyl ring of E 2 B form edge-to-face π-π interactions, which is energetically the most favourable among different π-π interactions [47] .
Enzyme interaction with E 2 B in the ternary complex
In the 17β-HSD1-E 2 B-NADP + ternary complex, the hydrogen bond with Ser 142 is conserved, as in the binary complex, with additional new hydrogen-bond interactions making the E 2 Benzyme complex more stable energetically. The -OH at position 3 of the steroidal backbone of E 2 B (Figure 3) (3.21 Å) . At the O-17 position of E 2 B, the hydrogen-bonding interaction with Ser 142 is conserved in both the binary and the ternary complexes (Figure 3 ). There is a shift in the placement of the phenyl ring of E 2 B, making two additional hydrogen bonds with Oσ of Asn 152 (2.65 Å) and another with O of Leu 95 (3.06 Å). In the ternary complex the π-π interaction between the phenyl ring of E 2 B and Tyr 155 is maintained similarly to that in the binary complex, although there is a remarkable shift in the placement of the E 2 B phenyl ring compared with the binary complex ( Figure 2C ). The methylene group at the C-16 position of the steroid E 2 facilitates the orientation of the phenyl ring. The shortest distance in the ternary complex between the two nearest phenyl rings is 3.80 Å, compared with 4.3 Å in the binary complex. In both complexes, they form an edge-to-face π-π interaction, the most favoured π-π interaction reported by Hunter et al. [47] .
Enzyme interaction with NADP + in ternary complex
The major hydrogen-bond interactions for the cofactor are noted at the nicotinamide end of NADP + . In the former structure-function study [13] , it was found that the major interaction between the cofactor and enzyme happens at the ADP part. This is why the enzyme binding has a similar affinity to ADP or NADP + [13] , suggesting that the nicotinamide is relatively flexible in the complex. In the E 2 B ternary complex, it was observed that the benzylamide ring of the inhibitor in turn stabilizes this flexible nicotinamide part of the cofactor, another strong interaction leading to the compact fit in the active site.
DISCUSSION
Comparison of the binary and ternary complex interactions
The size of E 2 B is greater than E 2 due to the additional benzylamide group at the C-16 position. However, the volume of the active-site cavity, calculated using Pocket-finder, did not differ significantly between the E 2 ternary, E 2 B binary and E 2 B ternary structures. This suggests the volume occupancy at the active site of the enzyme by E 2 B is higher when compared with E 2 , as the benzylamide ring of E 2 B occupies a space in the active site which is not occupied by the native substrates of the enzyme. This is also confirmed by comparison of the E 2 ternary and E 2 B ternary structures ( Figure 4B ). The extra fitting of E 2 B does not interfere with the NADP + -binding site as confirmed by the structures as well as kinetic studies.
In the binary complex, the steroidal scaffold of inhibitor E 2 B shows one strong hydrogen bond directly with the -OH of Ser 142 (2.58 Å) which is also found in the ternary complex. In the ternary complex, E 2 B interacts with the enzyme by forming three additional hydrogen bonds, of which two result from the -OH of its benzylamide ring (Figure 3) . The electron-density map strongly suggests that, in the binary complex, the benzylamide ring can manifest two conformations ( Figure 2C ). In the ternary complex, the presence of the nicotinamide ring of the cofactor stabilizes the positioning of the inhibitor, ensuring a more compact fit. The B-factor average of the E 2 B inhibitor is higher in the binary than in the ternary complex, with the highest difference coming from the benzylamide part of E 2 B.
The phenyl ring of Phe 192 in the binary and ternary complex shows a displacement ( Figure 4C ). In the absence of the cofactor (NADP + ), there is a strong possibility of forming a hydrogen bond between the amide group of E 2 B and Phe 192 . This interaction is absent from the ternary complex where the E 2 B displacement compared with its position in binary makes possible the hydrogen bond between the NO* of NADP + and -OH of Tyr 155 (3.32 Å). The aromatic rings of the E 2 B inhibitor with Phe  192 and the Tyr   155 demonstrate a π-stacking interaction, similar to that defined by Hunter et al. [47] . From the ternary complex, it is clear that E 2 B does not compete with the cofactor. 
Comparison of 17β-HSD1 structures in complex with E 2 B and those with other ligands
EM-1745 is the only inhibitor of 17β-HSD1 with which an enzyme-inhibitor complex structure has been reported [35] . Although the K i for EM-1745 and E 2 B are similar, i.e. 3.0 + − 0.8 and 0.9 + − 0.15 nM respectively, the IC 50 values of EM-1745 for cell homogenate is 52 nM, but for intact cells, it is 8 μM; the inhibitory curves were determined at 0.1 μM E 1 [48] , compared with an IC 50 of 42 nM for E 2 B in intact cells. The activity of E 2 B in intact cells as well as cell homogenate was almost the same (M. Mazumdar, D. Fournier, D.-W. Zhu, C. Cadot, D. Poirier and S.X. Lin, unpublished work), suggesting that its capacity for cell penetration is similar to that of natural steroids. This suggests that E 2 B is more accessible for the cells compared with EM-1745 in the present form, making E 2 B more drug-like.
As seen from the superposition of the substrates and the cofactors from the E 2 ternary with the E 2 B in binary and ternary complexes, the E 2 backbone in E 2 B and the NADP + of both ternary structures occupy almost the same position except that the benzylamide ring of E 2 B occupies a new position. The maximum variation in the active-site residues are observed in the loop region consisting of residues 189-201, which is the only flexible area surrounding the active site of the enzyme ( Figure 4D ). This additional interaction enhances the affinity of E 2 B with 17β-HSD1. EM-1745 with an adenine connected to the steroidal backbone, occupies partially the NADP + -binding site, whereas E 2 B does not interfere with the cofactor binding.
The aromatic-aromatic interactions between phenylalanine residues in proteins are known to play an important role in protein conformation. Although the energy of the π-π interaction is less than the electrostatic energy, being comparable with that of van der Waals interactions [47] , the formation of these π-π interactions between the phenyl rings plays an important role towards stabilizing and increasing the affinity of E 2 B for the enzyme. Hydrophobic interactions in the substrate-binding site of 17β-HSD1 contribute to the major binding energy. In this case, the placement of the three phenyl rings is stabilized by the π-π interactions [46] . This may be an important factor resulting in the high affinity and potency of this new inhibitor.
In both the binary and ternary structures, the phenyl ring of Tyr 155 and the benzylamide of E 2 B show π-π interactions, but when the distance between the two centroids is considered, the interaction is stronger in the ternary complex. The flexibility at the methylene group (C-21 position) of E 2 B allows the shift of the benzylamide ring in the presence of NADP + without perturbing the π-π interactions with Tyr 155 ( Figure 4C ). is maintained. NADP + also shows a modest shift in the E 2 B ternary complex when compared with its placement in the ternary complex of 17β-HSD1 and E 2 , its RMSD (root mean square deviation) being 0.528 Å.
When the position of the E 2 core in E 2 B is compared with the other available crystal structures in the PDB, it can be seen that there is a shift in the structures along the line of the steroid backbone ( Figure 4B ). A shift is also observed between the binary and ternary complexes of E 2 B with 17β-HSD1 (in the absence and presence of the cofactor). In the ternary complex, the movement is more towards the active-site core with respect to Tyr 155 , resulting in new interactions at the O3 position mentioned above. The E 2 backbone of E 2 B shows a stronger interaction between its O-17 and the Oγ of Ser 142 in the E 2 B complex with the enzyme than the same backbone in either the E 2 or the EM-1745 complexes considering the distance [36] .
In both binary and ternary complexes of 17β-HSD1 with E 2 B, the presence of a hydrogen-bond interaction with Oγ of Ser 142 renders the selectivity criterion for the present inhibitor. The interactions with His 221 are absent from the E 2 B complexes, and it was reported previously in the variation studies that His 221 is not an important residue for substrate recognition or binding [37] .
When the other complex structures of 17β-HSD1 with E 2 (1IOL), E 2 and NADP+ (1FDT), and EM-1745 (1I5R) are superimposed, a shift is seen at the active site for the E 2 core along the horizontal axis as mentioned. In the EM-1745 complex, the O-3 of the steroid scaffold is seen to be displaced away from Tyr 155 in order to adjust for the other interactions at the adenosine end of the inhibitor. The O-17 interaction with Ser 142 is lacking in the case of the EM-1745 complex [35] , which has been identified as an important interaction for substrate selectivity by the enzyme.
Loop region of 17β-HSD1
The loop region (residues 189-200) shows a shift in the ternary complex when compared with the binary complex. The maximum shift is observed for residues Phe 192 to Leu 195 . Comparison of the RMSD values from the various regions is presented in Table 2 . In the 2F o − F c map of both binary and ternary complexes, all residues in the loop have a clear electron density at the 1σ level, except for Met 193 in the ternary complex. The RMSD of the entire molecule and that of the loop region shows a significant difference ( Table 2 ). The loop seen in the ternary complex is adjusted so as to accommodate more space for the cofactor in the active site when compared with the binary complex. This loop region shows different conformation in various complexes solved to date [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] and is the only flexible region of the enzyme. In both complex structures of E 2 B the loop region is in, as seen in Figure 4 (D), a wider and more extended conformation, compared with the open conformation in the E 2 ternary complex. This additional space in the active site by the placement of the loop residues provides, first, enough space for the accommodation of the benzylamide ring of E 2 B and secondly, a compact fit of the substrate (E 2 B in this case) in the active site. In the complexes with E 2 B, it cannot be predicted whether the loop is in the closed or open conformation as reported by Sawicki et al. [32] , but the observed shift definitely results in a more spacious volume of the active site than that in the E 2 ternary complex.
Conclusion
Both hydrogen-bonding as well as van der Waals interactions are present in the interaction of the steroidal part of E 2 B, similar to those reported previously in other binary and ternary complexes of natural steroids, in 17β-HSD1 complexes. In the ternary complex, we observe that the presence of the cofactor results in a twist at the C-21 (methylene group linker), with the adjustment leading to an additional hydrogen-bonding interaction. The hydrogen-bonding suggests that the steroidal core of E 2 B interacts with the substratebinding site and the phenylamide group interacts with a second subsite. The latter is neither the site of the natural substrate nor that of the cofactor, but an additional space in the active site to interact with the shifted residues in the loop region. This produces a more compact occupation, thereby leaving very little space unoccupied at the active site. 17β-HSD1 is known to obey a Bi Bi mechanism, by which it binds to the cofactor first followed by the substrate, hence a desirable candidate inhibitor should be non-competitive with respect to the cofactor [49] . A hybrid inhibitor having both the substrate and cofactor parts, such as EM-1745, can compete with the substrate as well as the cofactor cores which is not the case with E 2 B.
From the ternary and binary structures, the following properties of E 2 B can be seen: (i) lower B-factor of E 2 B in the ternary complex structure than in the binary; (ii) unique electron density for the single conformation at the benzylamide of E 2 B in the ternary complex compared with the binary complex which shows two possible conformations; (iii) additional hydrogen bond at the steroidal core and the benzylamide ring with the enzyme in the ternary complex; and (iv) the non-competitive nature of E 2 B with the cofactor, as seen from the ternary structure, renders E 2 B a potential candidate as an inhibitor of 17β-HSD1 in breast cancer cells and maybe also in animal models. This compound needs to be explored further for the development of additional 17β-HSD1 inhibitors in order to advance adjuvant therapy for breast cancer along with SERMs (selective ER modulators), by suppressing the E 2 accumulation.
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